Description
COMPETACT is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already being treated with a combination of pioglitazone and metformin, or whose diabetes is not being adequately controlled with metformin alone, or in those patients who had initially responded to pioglitazone alone and who required additional glycemic control.
Management of type 2 diabetes should also include nutritional advice, weight reduction as needed, and exercise. These efforts are important not only in the primary treatment of type 2 diabetes, but also in maintaining the effectiveness of the drug.
After starting treatment with pioglitazone, patients should be evaluated every 3 to 6 months to ensure an adequate response to treatment (eg reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. Due to the potential risks with long-term treatment, it should be confirmed that the benefits of pioglitazone are sustained at subsequent routine visits.
Reviews
There are no reviews yet.